Skip to main content
Erschienen in: Journal of Neural Transmission 8/2011

01.08.2011 | Movement Disorders - CONy Pro/Con debate

Is all cognitive impairment in Parkinson’s disease “mild cognitive impairment”?

verfasst von: Saül Martínez-Horta, Jaime Kulisevsky

Erschienen in: Journal of Neural Transmission | Ausgabe 8/2011

Einloggen, um Zugang zu erhalten

Abstract

Cognitive impairment can be demonstrated in Parkinson’s disease (PD) from the very beginning of the disease. Clinical manifestations range from slight deficits, only demonstrable by means of neuropsychological testing, up to dementia. If a linear involution is supposed for the cognitive worsening in PD, then the relatively subtle cognitive defects should be taken as the earliest signs of dementia implying that PD-MCI concept would be thoroughly equivalent to that used for the early prediction of other dementias among healthy population. Cognitive defects in PD, however, may not follow a normal distribution. While fronto-striatal deficits, such as working memory, set-shifting and free-recall verbal memory appear altered in most patients during long periods of time, certain functions depending on more posterior-cortical regions, such as copying or naming, usually characterize patients with dementia. Fronto-striatal and posterior-cortical cognitive defects may have a different pathophysiological substrates, evolution and prognosis. While fronto-striatal defects appear more related to dopaminergic defects, posterior-cortical defects may obey multiple neurotransmitter failure. Designing criteria to accurately diagnose PD-MCI is highly relevant for clinical treatment, research, care-giving and decision-making. Besides quantitative defects, an operative definition of MCI in PD should clearly distinguish a “risky cognitive profile” among the broad cognitive defects intrinsic to PD. Thus, along with other possible biological markers, from a neuropsychological point of view, posterior-cortical defects probably represent the very syndrome of MCI in PD.
Literatur
Zurück zum Zitat Aarsland D, Kurz MW (2010) The epidemiology of dementia associated with Parkinson’s disease. Brain Pathol 20(3):633–639PubMedCrossRef Aarsland D, Kurz MW (2010) The epidemiology of dementia associated with Parkinson’s disease. Brain Pathol 20(3):633–639PubMedCrossRef
Zurück zum Zitat Aarsland D, Andersen K, Larsen JP, Lolk A, Kragh-Sorensen P (2003) Prevalence and characteristics of dementia in Parkinson disease: an 8 year prospective study. Arch Neurol 60(3):387–392PubMedCrossRef Aarsland D, Andersen K, Larsen JP, Lolk A, Kragh-Sorensen P (2003) Prevalence and characteristics of dementia in Parkinson disease: an 8 year prospective study. Arch Neurol 60(3):387–392PubMedCrossRef
Zurück zum Zitat Aarsland D, Bronnick K, Ehrt U, De Deyn PP, Tekin S, Emre M, Cummings JL (2007a) Neuropsychiatric symptoms in patients with Parkinson’s disease and dementia: frequency, profile and associated care giver stress. J Neurol Neurosurg Psychiatry 78(1):36–42PubMedCrossRef Aarsland D, Bronnick K, Ehrt U, De Deyn PP, Tekin S, Emre M, Cummings JL (2007a) Neuropsychiatric symptoms in patients with Parkinson’s disease and dementia: frequency, profile and associated care giver stress. J Neurol Neurosurg Psychiatry 78(1):36–42PubMedCrossRef
Zurück zum Zitat Aarsland D, Kvaloy JT, Andersen K, Larsen JP, Tang MX, Lolk A, Kragh-Sorensen P, Marder K (2007b) The effect of age of onset of PD on risk of dementia. J Neurol 254(1):38–45PubMedCrossRef Aarsland D, Kvaloy JT, Andersen K, Larsen JP, Tang MX, Lolk A, Kragh-Sorensen P, Marder K (2007b) The effect of age of onset of PD on risk of dementia. J Neurol 254(1):38–45PubMedCrossRef
Zurück zum Zitat Aarsland D, Bronnick K, Larsen JP, Tysnes OB, Alves G (2009) Cognitive impairment in incident, untreated Parkinson disease: the Norwegian ParkWest study. Neurology 72(13):1121–1126PubMedCrossRef Aarsland D, Bronnick K, Larsen JP, Tysnes OB, Alves G (2009) Cognitive impairment in incident, untreated Parkinson disease: the Norwegian ParkWest study. Neurology 72(13):1121–1126PubMedCrossRef
Zurück zum Zitat Aarsland D, Bronnick K, Williams-Gray C, Weintraub D, Marder K, Kulisevsky J, Burn D, Barone P, Pagonabarraga J, Allcock L, Santangelo G, Foltynie T, Janvin C, Larsen JP, Barker RA, Emre M (2010) Mild cognitive impairment in Parkinson disease: a multicenter pooled analysis. Neurology 75(12):1062–1069PubMedCrossRef Aarsland D, Bronnick K, Williams-Gray C, Weintraub D, Marder K, Kulisevsky J, Burn D, Barone P, Pagonabarraga J, Allcock L, Santangelo G, Foltynie T, Janvin C, Larsen JP, Barker RA, Emre M (2010) Mild cognitive impairment in Parkinson disease: a multicenter pooled analysis. Neurology 75(12):1062–1069PubMedCrossRef
Zurück zum Zitat Aarsland D, Muñiz G, Matthews F (2011) Nonlinear decline of mini-mental state examination in Parkinson’s disease. Mov Disord 26(2):334–337PubMedCrossRef Aarsland D, Muñiz G, Matthews F (2011) Nonlinear decline of mini-mental state examination in Parkinson’s disease. Mov Disord 26(2):334–337PubMedCrossRef
Zurück zum Zitat Buter TC, van den Hout A, Matthews FE, Larsen JP, Brayne C, Aarsland D (2008) Dementia and survival in Parkinson disease: a 12-year population study. Neurology 70(13):1017–1022PubMedCrossRef Buter TC, van den Hout A, Matthews FE, Larsen JP, Brayne C, Aarsland D (2008) Dementia and survival in Parkinson disease: a 12-year population study. Neurology 70(13):1017–1022PubMedCrossRef
Zurück zum Zitat Caviness JN, Driver-Dunckley E, Connor DJ, Sabbagh MN, Hentz JG, Noble B, Evidente VG, Shill HA, Adler CH (2007) Defining mild cognitive impairment in Parkinson’s disease. Mov Disord 22(9):1272–1277PubMedCrossRef Caviness JN, Driver-Dunckley E, Connor DJ, Sabbagh MN, Hentz JG, Noble B, Evidente VG, Shill HA, Adler CH (2007) Defining mild cognitive impairment in Parkinson’s disease. Mov Disord 22(9):1272–1277PubMedCrossRef
Zurück zum Zitat Cools R, Stefanova E, Barker RA, Robbins TW, Owen AM (2002) Dopaminergic modulation of high-level cognition in Parkinson’s disease: the role of the prefrontal cortex revealed by PET. Brain 125(Pt 3):584–594PubMedCrossRef Cools R, Stefanova E, Barker RA, Robbins TW, Owen AM (2002) Dopaminergic modulation of high-level cognition in Parkinson’s disease: the role of the prefrontal cortex revealed by PET. Brain 125(Pt 3):584–594PubMedCrossRef
Zurück zum Zitat Cools R, Lewis SJ, Clark L, Barker RA, Robbins TW (2007) L-DOPA disrupts activity in the nucleus accumbens during reversal learning in Parkinson’s disease. Neuropsychopharmacology 32(1):180–189PubMedCrossRef Cools R, Lewis SJ, Clark L, Barker RA, Robbins TW (2007) L-DOPA disrupts activity in the nucleus accumbens during reversal learning in Parkinson’s disease. Neuropsychopharmacology 32(1):180–189PubMedCrossRef
Zurück zum Zitat Dalrymple-Alford JC, Livingston L, Macaskill MR, Graham C, Melzer TR, Porter RJ, Watts R, Anderson TJ (2011) Characterizing mild cognitive impairment in Parkinson’s disease. Mov Disord Dalrymple-Alford JC, Livingston L, Macaskill MR, Graham C, Melzer TR, Porter RJ, Watts R, Anderson TJ (2011) Characterizing mild cognitive impairment in Parkinson’s disease. Mov Disord
Zurück zum Zitat Dujardin K, Sockeel P, Delliaux M, Destee A, Defebvre L (2009) Apathy may herald cognitive decline and dementia in Parkinson’s disease. Mov Disord 24(16):2391–2397PubMed Dujardin K, Sockeel P, Delliaux M, Destee A, Defebvre L (2009) Apathy may herald cognitive decline and dementia in Parkinson’s disease. Mov Disord 24(16):2391–2397PubMed
Zurück zum Zitat Emre M, Aarsland D, Brown R, Burn DJ, Duyckaerts C, Mizuno Y, Broe GA, Cummings J, Dickson DW, Gauthier S, Goldman J, Goetz C, Korczyn A, Lees A, Levy R, Litvan I, McKeith I, Olanow W, Poewe W, Quinn N, Sampaio C, Tolosa E, Dubois B (2007) Clinical diagnostic criteria for dementia associated with Parkinson’s disease. Mov Disord 22(12):1689–1707PubMedCrossRef Emre M, Aarsland D, Brown R, Burn DJ, Duyckaerts C, Mizuno Y, Broe GA, Cummings J, Dickson DW, Gauthier S, Goldman J, Goetz C, Korczyn A, Lees A, Levy R, Litvan I, McKeith I, Olanow W, Poewe W, Quinn N, Sampaio C, Tolosa E, Dubois B (2007) Clinical diagnostic criteria for dementia associated with Parkinson’s disease. Mov Disord 22(12):1689–1707PubMedCrossRef
Zurück zum Zitat Foltynie T, Brayne CE, Robbins TW, Barker RA (2004) The cognitive ability of an incident cohort of Parkinson’s patients in the UK: the campaign study. Brain 127(Pt 3):550–560PubMed Foltynie T, Brayne CE, Robbins TW, Barker RA (2004) The cognitive ability of an incident cohort of Parkinson’s patients in the UK: the campaign study. Brain 127(Pt 3):550–560PubMed
Zurück zum Zitat Galvin JE (2006) Cognitive change in Parkinson disease. Alzheimer Dis Assoc Disord 20(4):302–310PubMedCrossRef Galvin JE (2006) Cognitive change in Parkinson disease. Alzheimer Dis Assoc Disord 20(4):302–310PubMedCrossRef
Zurück zum Zitat Galvin JE, Pollack J, Morris JC (2006) Clinical phenotype of Parkinson disease dementia. Neurology 67(9):1605–1611PubMedCrossRef Galvin JE, Pollack J, Morris JC (2006) Clinical phenotype of Parkinson disease dementia. Neurology 67(9):1605–1611PubMedCrossRef
Zurück zum Zitat Hely MA, Reid WG, Adena MA, Halliday GM, Morris JG (2008) The Sydney multicenter study of Parkinson’s disease: the inevitability of dementia at 20 years. Mov Disord 23(6):837–844PubMedCrossRef Hely MA, Reid WG, Adena MA, Halliday GM, Morris JG (2008) The Sydney multicenter study of Parkinson’s disease: the inevitability of dementia at 20 years. Mov Disord 23(6):837–844PubMedCrossRef
Zurück zum Zitat Hosokai Y, Nishio Y, Hirayama K, Takeda A, Ishioka T, Sawada Y, Suzuki K, Itoyama Y, Takahashi S, Fukuda H, Mori E (2009) Distinct patterns of regional cerebral glucose metabolism in Parkinson’s disease with and without mild cognitive impairment. Mov Disord 24(6):854–862PubMedCrossRef Hosokai Y, Nishio Y, Hirayama K, Takeda A, Ishioka T, Sawada Y, Suzuki K, Itoyama Y, Takahashi S, Fukuda H, Mori E (2009) Distinct patterns of regional cerebral glucose metabolism in Parkinson’s disease with and without mild cognitive impairment. Mov Disord 24(6):854–862PubMedCrossRef
Zurück zum Zitat Janvin CC, Larsen JP, Aarsland D, Hugdahl K (2006a) Subtypes of mild cognitive impairment in Parkinson’s disease: progression to dementia. Mov Disord 21(9):1343–1349PubMedCrossRef Janvin CC, Larsen JP, Aarsland D, Hugdahl K (2006a) Subtypes of mild cognitive impairment in Parkinson’s disease: progression to dementia. Mov Disord 21(9):1343–1349PubMedCrossRef
Zurück zum Zitat Janvin CC, Larsen JP, Salmon DP, Galasko D, Hugdahl K, Aarsland D (2006b) Cognitive profiles of individual patients with Parkinson’s disease and dementia: comparison with dementia with lewy bodies and Alzheimer’s disease. Mov Disord 21(3):337–342PubMedCrossRef Janvin CC, Larsen JP, Salmon DP, Galasko D, Hugdahl K, Aarsland D (2006b) Cognitive profiles of individual patients with Parkinson’s disease and dementia: comparison with dementia with lewy bodies and Alzheimer’s disease. Mov Disord 21(3):337–342PubMedCrossRef
Zurück zum Zitat Kulisevsky J (2000) Role of dopamine in learning and memory: implications for the treatment of cognitive dysfunction in patients with Parkinson’s disease. Drugs Aging 16(5):365–379PubMedCrossRef Kulisevsky J (2000) Role of dopamine in learning and memory: implications for the treatment of cognitive dysfunction in patients with Parkinson’s disease. Drugs Aging 16(5):365–379PubMedCrossRef
Zurück zum Zitat Kulisevsky J, Pagonabarraga J (2009) Cognitive impairment in Parkinson’s disease: tools for diagnosis and assessment. Mov Disord 24(8):1103–1110PubMedCrossRef Kulisevsky J, Pagonabarraga J (2009) Cognitive impairment in Parkinson’s disease: tools for diagnosis and assessment. Mov Disord 24(8):1103–1110PubMedCrossRef
Zurück zum Zitat Kulisevsky J, Avila A, Barbanoj M, Antonijoan R, Berthier ML, Gironell A (1996) Acute effects of levodopa on neuropsychological performance in stable and fluctuating Parkinson’s disease patients at different levodopa plasma levels. Brain 119(Pt 6):2121–2132PubMedCrossRef Kulisevsky J, Avila A, Barbanoj M, Antonijoan R, Berthier ML, Gironell A (1996) Acute effects of levodopa on neuropsychological performance in stable and fluctuating Parkinson’s disease patients at different levodopa plasma levels. Brain 119(Pt 6):2121–2132PubMedCrossRef
Zurück zum Zitat Kulisevsky J, Garcia-Sanchez C, Berthier ML, Barbanoj M, Pascual-Sedano B, Gironell A, Estevez-Gonzalez A (2000) Chronic effects of dopaminergic replacement on cognitive function in Parkinson’s disease: a two-year follow-up study of previously untreated patients. Mov Disord 15(4):613–626PubMedCrossRef Kulisevsky J, Garcia-Sanchez C, Berthier ML, Barbanoj M, Pascual-Sedano B, Gironell A, Estevez-Gonzalez A (2000) Chronic effects of dopaminergic replacement on cognitive function in Parkinson’s disease: a two-year follow-up study of previously untreated patients. Mov Disord 15(4):613–626PubMedCrossRef
Zurück zum Zitat Kulisevsky J, Pagonabarraga J, Pascual-Sedano B, Garcia-Sanchez C, Gironell A (2008) Prevalence and correlates of neuropsychiatric symptoms in Parkinson’s disease without dementia. Mov Disord 23(13):1889–1896PubMedCrossRef Kulisevsky J, Pagonabarraga J, Pascual-Sedano B, Garcia-Sanchez C, Gironell A (2008) Prevalence and correlates of neuropsychiatric symptoms in Parkinson’s disease without dementia. Mov Disord 23(13):1889–1896PubMedCrossRef
Zurück zum Zitat Lees AJ, Smith E (1983) Cognitive deficits in the early stages of Parkinson’s disease. Brain 106(Pt 2):257–270PubMedCrossRef Lees AJ, Smith E (1983) Cognitive deficits in the early stages of Parkinson’s disease. Brain 106(Pt 2):257–270PubMedCrossRef
Zurück zum Zitat Llebaria G, Pagonabarraga J, Martinez-Corral M, Garcia-Sanchez C, Pascual-Sedano B, Gironell A, Kulisevsky J (2010) Neuropsychological correlates of mild to severe hallucinations in Parkinson’s disease. Mov Disord 25(16):2785–2791PubMedCrossRef Llebaria G, Pagonabarraga J, Martinez-Corral M, Garcia-Sanchez C, Pascual-Sedano B, Gironell A, Kulisevsky J (2010) Neuropsychological correlates of mild to severe hallucinations in Parkinson’s disease. Mov Disord 25(16):2785–2791PubMedCrossRef
Zurück zum Zitat Lyoo CH, Jeong Y, Ryu YH, Rinne JO, Lee MS (2010) Cerebral glucose metabolism of Parkinson’s disease patients with mild cognitive impairment. Eur Neurol 64(2):65–73PubMedCrossRef Lyoo CH, Jeong Y, Ryu YH, Rinne JO, Lee MS (2010) Cerebral glucose metabolism of Parkinson’s disease patients with mild cognitive impairment. Eur Neurol 64(2):65–73PubMedCrossRef
Zurück zum Zitat Muslimovic D, Post B, Speelman JD, Schmand B (2005) Cognitive profile of patients with newly diagnosed Parkinson disease. Neurology 65(8):1239–1245PubMedCrossRef Muslimovic D, Post B, Speelman JD, Schmand B (2005) Cognitive profile of patients with newly diagnosed Parkinson disease. Neurology 65(8):1239–1245PubMedCrossRef
Zurück zum Zitat Pagonabarraga J, Kulisevsky J, Llebaria G, Garcia-Sanchez C, Pascual-Sedano B, Gironell A (2008) Parkinson’s disease-cognitive rating scale: a new cognitive scale specific for Parkinson’s disease. Mov Disord 23(7):998–1005PubMedCrossRef Pagonabarraga J, Kulisevsky J, Llebaria G, Garcia-Sanchez C, Pascual-Sedano B, Gironell A (2008) Parkinson’s disease-cognitive rating scale: a new cognitive scale specific for Parkinson’s disease. Mov Disord 23(7):998–1005PubMedCrossRef
Zurück zum Zitat Petersen RC (2004) Mild cognitive impairment as a diagnostic entity. J Intern Med 256(3):183–194PubMedCrossRef Petersen RC (2004) Mild cognitive impairment as a diagnostic entity. J Intern Med 256(3):183–194PubMedCrossRef
Zurück zum Zitat Petersen RC, Smith GE, Waring SC, Ivnik RJ, Kokmen E, Tangelos EG (1997) Aging, memory, and mild cognitive impairment. Int Psychogeriatr 9(Suppl 1):65–69PubMedCrossRef Petersen RC, Smith GE, Waring SC, Ivnik RJ, Kokmen E, Tangelos EG (1997) Aging, memory, and mild cognitive impairment. Int Psychogeriatr 9(Suppl 1):65–69PubMedCrossRef
Zurück zum Zitat Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E (1999) Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 56(3):303–308PubMedCrossRef Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E (1999) Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 56(3):303–308PubMedCrossRef
Zurück zum Zitat Petersen RC, Doody R, Kurz A, Mohs RC, Morris JC, Rabins PV, Ritchie K, Rossor M, Thal L, Winblad B (2001a) Current concepts in mild cognitive impairment. Arch Neurol 58(12):1985–1992PubMedCrossRef Petersen RC, Doody R, Kurz A, Mohs RC, Morris JC, Rabins PV, Ritchie K, Rossor M, Thal L, Winblad B (2001a) Current concepts in mild cognitive impairment. Arch Neurol 58(12):1985–1992PubMedCrossRef
Zurück zum Zitat Petersen RC, Stevens JC, Ganguli M, Tangalos EG, Cummings JL, DeKosky ST (2001b) Practice parameter: early detection of dementia: mild cognitive impairment (an evidence-based review): report of the quality standards subcommittee of the american academy of neurology. Neurology 56(9):1133–1142PubMed Petersen RC, Stevens JC, Ganguli M, Tangalos EG, Cummings JL, DeKosky ST (2001b) Practice parameter: early detection of dementia: mild cognitive impairment (an evidence-based review): report of the quality standards subcommittee of the american academy of neurology. Neurology 56(9):1133–1142PubMed
Zurück zum Zitat Riedel O, Klotsche J, Spottke A, Deuschl G, Forstl H, Henn F, Heuser I, Oertel W, Reichmann H, Riederer P, Trenkwalder C, Dodel R, Wittchen HU (2008) Cognitive impairment in 873 patients with idiopathic Parkinson’s disease: results from the german study on epidemiology of parkinson’s disease with dementia (GEPAD). J Neurol 255(2):255–264PubMedCrossRef Riedel O, Klotsche J, Spottke A, Deuschl G, Forstl H, Henn F, Heuser I, Oertel W, Reichmann H, Riederer P, Trenkwalder C, Dodel R, Wittchen HU (2008) Cognitive impairment in 873 patients with idiopathic Parkinson’s disease: results from the german study on epidemiology of parkinson’s disease with dementia (GEPAD). J Neurol 255(2):255–264PubMedCrossRef
Zurück zum Zitat Rowe JB, Hughes L, Ghosh BC, Eckstein D, Williams-Gray CH, Fallon S, Barker RA, Owen AM (2008) Parkinson’s disease and dopaminergic therapy–differential effects on movement, reward and cognition. Brain 131(Pt 8):2094–2105PubMedCrossRef Rowe JB, Hughes L, Ghosh BC, Eckstein D, Williams-Gray CH, Fallon S, Barker RA, Owen AM (2008) Parkinson’s disease and dopaminergic therapy–differential effects on movement, reward and cognition. Brain 131(Pt 8):2094–2105PubMedCrossRef
Zurück zum Zitat Setó-Salvià N, Clarimón J, Pagonabarraga J, Pascual-Sedano B, Campolongo A, Combarros O, Mateo JI, Regaña D, Martínez-Corral M, Marquié M, Alcolea D, Suárez-Calvet M, Molina-Porcel L, Dols O, Gómez-Isla T, Blesa R, Lleó A, Kulisevsky J (2011) Dementia risk in Parkinson disease: disentangling the role of MAPT haplotypes. Arch Neurol 68(3):359–364 Setó-Salvià N, Clarimón J, Pagonabarraga J, Pascual-Sedano B, Campolongo A, Combarros O, Mateo JI, Regaña D, Martínez-Corral M, Marquié M, Alcolea D, Suárez-Calvet M, Molina-Porcel L, Dols O, Gómez-Isla T, Blesa R, Lleó A, Kulisevsky J (2011) Dementia risk in Parkinson disease: disentangling the role of MAPT haplotypes. Arch Neurol 68(3):359–364
Zurück zum Zitat Stern Y, Marder K, Tang MX, Mayeux R (1993) Antecedent clinical features associated with dementia in Parkinson’s disease. Neurology 43(9):1690–1692PubMed Stern Y, Marder K, Tang MX, Mayeux R (1993) Antecedent clinical features associated with dementia in Parkinson’s disease. Neurology 43(9):1690–1692PubMed
Zurück zum Zitat Troster AI (2008) Neuropsychological characteristics of dementia with Lewy bodies and Parkinson’s disease with dementia: differentiation, early detection, and implications for “mild cognitive impairment” and biomarkers. Neuropsychol Rev 18(1):103–119PubMedCrossRef Troster AI (2008) Neuropsychological characteristics of dementia with Lewy bodies and Parkinson’s disease with dementia: differentiation, early detection, and implications for “mild cognitive impairment” and biomarkers. Neuropsychol Rev 18(1):103–119PubMedCrossRef
Zurück zum Zitat Williams-Gray CH, Foltynie T, Brayne CE, Robbins TW, Barker RA (2007) Evolution of cognitive dysfunction in an incident Parkinson’s disease cohort. Brain 130(Pt 7):1787–1798PubMedCrossRef Williams-Gray CH, Foltynie T, Brayne CE, Robbins TW, Barker RA (2007) Evolution of cognitive dysfunction in an incident Parkinson’s disease cohort. Brain 130(Pt 7):1787–1798PubMedCrossRef
Zurück zum Zitat Williams-Gray CH, Evans JR, Goris A, Foltynie T, Ban M, Robbins TW, Brayne C, Kolachana BS, Weinberger DR, Sawcer SJ, Barker RA (2009) The distinct cognitive syndromes of Parkinson’s disease: 5 year follow-up of the CamPaIGN cohort. Brain 132(Pt 11):2958–2969PubMedCrossRef Williams-Gray CH, Evans JR, Goris A, Foltynie T, Ban M, Robbins TW, Brayne C, Kolachana BS, Weinberger DR, Sawcer SJ, Barker RA (2009) The distinct cognitive syndromes of Parkinson’s disease: 5 year follow-up of the CamPaIGN cohort. Brain 132(Pt 11):2958–2969PubMedCrossRef
Zurück zum Zitat Yeterian EH, Pandya DN (1991a) Corticothalamic connections of the superior temporal sulcus in rhesus monkeys. Exp Brain Res 83(2):268–284PubMedCrossRef Yeterian EH, Pandya DN (1991a) Corticothalamic connections of the superior temporal sulcus in rhesus monkeys. Exp Brain Res 83(2):268–284PubMedCrossRef
Zurück zum Zitat Yeterian EH, Pandya DN (1991b) Prefrontostriatal connections in relation to cortical architectonic organization in rhesus monkeys. J Comp Neurol 312(1):43–67PubMedCrossRef Yeterian EH, Pandya DN (1991b) Prefrontostriatal connections in relation to cortical architectonic organization in rhesus monkeys. J Comp Neurol 312(1):43–67PubMedCrossRef
Metadaten
Titel
Is all cognitive impairment in Parkinson’s disease “mild cognitive impairment”?
verfasst von
Saül Martínez-Horta
Jaime Kulisevsky
Publikationsdatum
01.08.2011
Verlag
Springer Vienna
Erschienen in
Journal of Neural Transmission / Ausgabe 8/2011
Print ISSN: 0300-9564
Elektronische ISSN: 1435-1463
DOI
https://doi.org/10.1007/s00702-011-0675-9

Weitere Artikel der Ausgabe 8/2011

Journal of Neural Transmission 8/2011 Zur Ausgabe

Basic Neurosciences, Genetics and Immunology - CONy Pro/Con debate

Should mechanical embolectomy devices be used in routine clinical practice?

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Akuter Schwindel: Wann lohnt sich eine MRT?

28.04.2024 Schwindel Nachrichten

Akuter Schwindel stellt oft eine diagnostische Herausforderung dar. Wie nützlich dabei eine MRT ist, hat eine Studie aus Finnland untersucht. Immerhin einer von sechs Patienten wurde mit akutem ischämischem Schlaganfall diagnostiziert.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Viel Bewegung in der Parkinsonforschung

25.04.2024 Parkinson-Krankheit Nachrichten

Neue arznei- und zellbasierte Ansätze, Frühdiagnose mit Bewegungssensoren, Rückenmarkstimulation gegen Gehblockaden – in der Parkinsonforschung tut sich einiges. Auf dem Deutschen Parkinsonkongress ging es auch viel um technische Innovationen.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.